Levi & Korsinsky Investigates Teleflex Incorporated: Urology Business Split, CFO Resignation, and Acquisition Raise Securities Law Concerns
New York, NY – March 5, 2025
Levi & Korsinsky, a leading securities law firm, notifies investors that it has commenced an investigation into Teleflex Incorporated (NYSE: TFX) over potential securities law violations. The investigation comes in the wake of several significant corporate developments announced by the medical technology company on February 27, 2025:
Business Split and Public Offering
Teleflex Incorporated revealed plans to split off its Urology, Acute Care, and OEM businesses into a new publicly traded company. The transaction is expected to be completed through a tax-free distribution to Teleflex shareholders. The new company, yet to be named, will operate as a standalone entity and is expected to be listed on the New York Stock Exchange.
Chief Financial Officer Resignation
In conjunction with the business split, Teleflex announced the resignation of its Chief Financial Officer, Michael McManus, effective March 31, 2025. He will be replaced by the current Vice President of Finance and Business Development, William “Bill” Hawkins.
Acquisition of BIOTRONIK SE’s Vascular Intervention Business
Teleflex also announced its intention to acquire all of the vascular intervention business of BIOTRONIK SE for an estimated cash payment of about €760M. This acquisition is expected to strengthen Teleflex’s presence in the vascular intervention market and provide opportunities for growth.
Investors who purchased Teleflex securities between February 27, 2025 and the present may be able to recover their losses through the investigation. To get more information, investors are encouraged to contact Levi & Korsinsky at (212) 363-7500 or via email at [email protected].
Implications for Individual Investors
As an individual investor, the events at Teleflex Incorporated could potentially impact your investment portfolio in several ways:
- Increased volatility: The combination of a business split, CFO resignation, and a significant acquisition can create uncertainty and potentially lead to increased volatility in the stock price.
- Dilution: The creation of a new publicly traded company through the business split could potentially dilute the value of existing Teleflex shareholders.
- Risk: The acquisition of a new business comes with its own set of risks, including integration challenges and potential regulatory hurdles.
Global Implications
Beyond individual investors, the events at Teleflex Incorporated could also have wider implications:
- Competitive landscape: The acquisition of BIOTRONIK SE’s vascular intervention business could potentially shift the competitive landscape in the medical technology industry.
- Regulatory environment: The acquisition could also be subject to regulatory review, particularly in Europe where BIOTRONIK SE is headquartered.
- Market trends: The split of Teleflex’s Urology, Acute Care, and OEM businesses into a separate entity could be indicative of broader trends in the medical technology industry.
As the investigation by Levi & Korsinsky unfolds, it will be important for investors to stay informed about the latest developments at Teleflex Incorporated and how they may be impacted.
Conclusion
The events at Teleflex Incorporated, including the planned business split, CFO resignation, and acquisition of BIOTRONIK SE’s vascular intervention business, have raised concerns over potential securities law violations. Levi & Korsinsky is investigating these matters on behalf of investors and encourages those with losses to contact the firm for more information. For individual investors, these events could lead to increased volatility, dilution, and risks, while for the wider market, they could have implications for the competitive landscape, regulatory environment, and market trends.
As always, it is essential to stay informed and consult with a financial advisor or legal counsel if you have any concerns about your investments.
